Market Research Report
Tuberculosis - Pipeline Review, H2 2020
|Published by||Global Markets Direct||Product code||232861|
|Published||Content info||419 Pages
Delivery time: 1-2 business days
|Tuberculosis - Pipeline Review, H2 2020|
|Published: November 30, 2020||Content info: 419 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 11, 8, 1, 63, 35 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 35 and 35 molecules, respectively.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Table of Contents
Tuberculosis- Therapeutics Development
Tuberculosis- Therapeutics Assessment
Tuberculosis- Companies Involved in Therapeutics Development
Tuberculosis- Drug Profiles
Tuberculosis- Dormant Projects
Tuberculosis- Discontinued Products
Tuberculosis- Product Development Milestones